$MGRX News

Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market Close

Mangoceuticals Closes Registered Direct Offering Following $2.5M Strategic Investment Commitment In MangoRx IP Holdings To Support Intellectual Property Commercialization

Mangoceuticals (MGRX) Shares Fall 12% After Hours: Here's Why

Mangoceuticals’ MangoRx IP Secures $2.5M Investment From Strategic Investors, Receives Initial $1.75M Tranche

On Aug 19, Mangoceuticals And Nuclea Energy Terminate Business Combination Agreement; Pipe Financing Minimum Of $15M Not Raised By Aug 21, 2026; Closing Conditions Not Met

Mangoceuticals Inc.’s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy’s Advanced Nuclear Technology Assets

Mangoceuticals’ Merger Partner, Nuclea Energy, Enters Into Definitive Agreement With Moltex Energy To Acquire Advanced Nuclear Technology Assets; Terms Undisclosed

Mangoceuticals (MGRX) Stock Jumps Over 49% After Hours: Here's Why

Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination

Mangoceuticals (MGRX) Stock Jumps 138% After Hours On Nuclear Reactor Deal: Here's Why It Is Trending

Mangoceuticals Q4 EPS $(0.13) Up From $(1.01) YoY, Sales $94.360K Down From $105.247K YoY

Mangoceuticals Stock Doubles After Texas Lawsuit

Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.

Mangoceuticals shares are trading higher after the company announced it filed a lawsuit against Clarity Ventures.

Mangoceuticals Files Civil Lawsuit Against Clarity Ventures For $73M; Alleges Clarity Failed To Deliver Fully Functional HIPAA-Compliant Enterprise Resource Planning And eCommerce Platform

Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

Mangoceuticals shares are trading higher after the company announced it filed a Patent Cooperation Treaty international application to secure broad global patent protection for the antiviral animal feed and drinking water additive technology that powers MGX-0024.

Mangoceuticals Files PCT International Application To Secure Global Patent Protection For Antiviral Animal Feed And Drinking Water Additive Technology Powering MGX-0024

Mangoceuticals’ Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study

Mangoceuticals Announces New Data From Its Proprietary Antiviral Compound MGX-0024